Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03481868
Other study ID # CHU-376
Secondary ID 2017-A01332-51
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2018
Est. completion date February 1, 2026

Study information

Verified date April 2024
Source University Hospital, Clermont-Ferrand
Contact Patrick LACARIN
Phone 04 73 75 11 95
Email placarin@chu-clermontferrand.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective : To identify epigenetic dysregulations of in vivo TKI-resisting CML cells Hypothesis : An epigenetic dysregulation is involved in the in vivo survival of a CML cell subclone despite the use of TKIs


Description:

Chronic myeloid leukemia (CML) is a model of leukemogenesis because the malignant transformation of a hematopoietic stem cell is considered as the consequence of a unique major event: the translocation t(9;22) which is able to produce the BCR-ABL chimeric protein. The treatment of CML has made considerable progress with the development of tyrosine kinase inhibitors (TKI) targeting the BCR-ABL protein activity. Despite the efficacy of these drugs, several studies showed the existence of intra-clonal heterogeneity and the in vivo survival of a leukemic stem cell (LSC) subset by: - A detectable residual disease in the majority of cases, and after treatment for several years. - The relapse of about half of patients after stopping TKI; these relapses are the proof of the in vivo persistence of LSC, even when CML clone is particularly sensitive to TKI. - Cases of unexplained TKI resistance (no BCR-ABL mutation etc…) The mechanisms involved in in vivo survival of LSC remain largely unknown. Mechanisms independent of BCR-ABL TK activity could be responsible of LSC survival. However, the fact that CML is the consequence of t(9; 22) if it appears in a HSC, suggests that a stem cell specific biological status should play a role in the emergence of the disease and probably the special feature of this cell subset. Several studies showed the essential role of epigenetic factors in stem cell behavior (quiescence, self-renewal, or differentiation process). Epigenetic dysregulation of some gene expression was observed in CML cells and changes in DNA methylation are involved in CML progression towards accelerated or blast phase, more resistant to TKIs. These observations led to clinical trial combining TKI with epigenetic drugs which results confirmed the in vivo involvement of epigenetic mechanisms during CML progression. However, the role of epigenetics in the early resistance of a chronic phase CML cell subset remains unknown. The hypothesis is that epigenetic features could participate in TKI resistance of CML LSC and their survival in bone marrow. In order to identify new mechanisms and/or new targets involved in LSC resistance, investigator choose a global approach of DNA methylation profile with an HM450K microarray. Investigator analyzed the sorted CML CD34+ CD15- cell subset (n=6) in comparison with: 1) CD34+ CD15- cells from healthy donors (hematopoietic grafts), in order to eliminate specificities of normal hematopoietic hierarchy, 2) the CD34-CD15+ sub-clone from the CML clone before any treatment in order to eliminate characteristic of CML mature compartment. The CD34+CD15- cells showed a specific DNA methylation profile, from diagnosis and from this level of cell hierarchy ((Bourgne et al., oral communication, SFH meeting 2017, manuscript submitted). In order to identify biomarkers specific to CML cells, investigator removed abnormally methylated regions that are differently methylated during hematopoietic differentiation. After this step, 825, 2210 and 1461 probes identified regions specifically dysmethylated in CD34-CD15+, CD34+ CD15- CML cells and both respectively. Investigator also observed changes in expression of epigenetic actors. These results validate our hypothesis. With the recent data published in literature, they strongly argue in favor of the involvement of epigenetic dysregulation in native intra-clonal heterogeneity, and justify this original translational research project.


Recruitment information / eligibility

Status Recruiting
Enrollment 160
Est. completion date February 1, 2026
Est. primary completion date May 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient newly diagnosed for Chronic Myeloid Leukemia in chronic phase - Patient older than 18 years old - Patient who received no treatment for CML at the time of sampling on D0 - Intention of prescription with first-line treatment with TKI only - Choice of first-line CML treatment by TKI only - Patient having signed an informed consent - Patient with a social security system Exclusion Criteria: - Contra-indication to the use of TKI - Probability of poor compliance during treatment - Patients already treated for CML

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Collection of blood and bone marrow
Collection of blood and bone marrow in order to identify epigenetic abnormalities and their consequences in surviving CML cells after 3 months of TKI treatment

Locations

Country Name City State
France CHU Annecy-Genevois Annecy
France Institut Bergonié Bordeaux
France CHU Caen Caen
France CHU Clermont-Ferrand Clermont-Ferrand
France CHU Grenoble Alpes Grenoble
France CHU Lille Lille
France Centre Léon Bérard Lyon
France Hospices Civils de Lyon Lyon
France CHU Nancy Nancy
France CHU Nice Nice
France Hôpital Bicêtre Paris
France Hôpital Henri Mondor Paris
France Hôpital Paul Brousse Paris
France Hôpital Saint Louis Paris
France CHU Saint-Etienne Saint-Étienne
France CHU Versailles Versailles

Sponsors (16)

Lead Sponsor Collaborator
University Hospital, Clermont-Ferrand AP-HP Hôpital Henri-Mondor, hematology department, AP-HP, hematology department, Centre Leon Berard, CH Annecy Genevois, CHRU Lille, hematology department, CHU Caen, hematology department, CHU Lyon, hematology department, CHU Nancy, hematology department, CHU Nice, hematology department, CHU Saint-Etienne, hematology department, Institut Bergonié Bordeaux, hematology department, Institut Paoli-Calmettes, Institut Universitaire du Cancer de Toulouse - Oncopole, hematology department, University Hospital, Grenoble, Versailles Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Epigenetic dysregulations of in vivo TKI-resisting CML cells Epigenetic and/or gene expression anomalies in in vivo TKI-selected CML cells for 3 months in comparison with anomalies identified at D0 at Day 0 and Month3
Secondary relationship between epigenetic/gene expression profile and CML burden (M3) Ratio BCR-ABL/ABL in bone marrow at Month 3
Secondary relationship between epigenetic/gene expression profile and the characteristics of patients Sokal / EUTOS at Day 0 and Month 3
Secondary early new biomarkers To identify in primary CML clones the shared epigenetic marks and/or deregulated genes of 3 months TKI-resistant cells and their relationship with CML burden at M3 at Day 0 and Month 3
See also
  Status Clinical Trial Phase
Terminated NCT01066468 - Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders. Phase 1
Completed NCT00428909 - Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Phase 1
Completed NCT04126707 - The Absorption, Metabolism and Excretion of [14C] HQP1351 in Humans Phase 1
Recruiting NCT02061800 - CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant Phase 1/Phase 2
Completed NCT00488592 - Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers Phase 2
Terminated NCT03615105 - Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors Phase 2
Recruiting NCT02790515 - Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Phase 2
Active, not recruiting NCT03849651 - TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies Phase 2
Completed NCT02363868 - Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population N/A
Withdrawn NCT01605981 - Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. Phase 4
Completed NCT00433745 - Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy Phase 2
Not yet recruiting NCT04709731 - Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia Phase 2
Recruiting NCT02889003 - Second STOP After Pioglitazone Priming in CML Patients Phase 2
Completed NCT02733445 - Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib N/A
Active, not recruiting NCT03746054 - Evaluation of a Cardiovascular Active Prevention in Chronic Myeloid Leukemia on the Cardiovascular Morbi-mortality Phase 3
Completed NCT01667133 - A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Phase 1/Phase 2
Completed NCT00720785 - Natural Killer Cells and Bortezomib to Treat Cancer Phase 1
Recruiting NCT05963061 - Chronic Myeloid Leukemia (CML) Real-Life Database
Approved for marketing NCT01592136 - Expanded Access Program of Ponatinib N/A